Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical Hydromorphone for Wound Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00177060
Recruitment Status : Terminated (No funding available.)
First Posted : September 15, 2005
Last Update Posted : March 1, 2010
Sponsor:
Information provided by:
University of Minnesota

Brief Summary:
The hypothesis is that topical opioids will hasten wound healing in humans.

Condition or disease Intervention/treatment Phase
Wound Healing Drug: hydromorphone Phase 1 Phase 2

Detailed Description:
This is based on our published data that morphine is a powerful stimulant of angiogenesis and our preclinical study of wounds in rats which demonstrate that topical opioids (morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on hydromorphone which was more powerful than morphine as a wound-healer in the rat study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Topical Hydromorphone for Wound Healing
Study Start Date : October 2003
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Healing rates and microvessel density will be compared statistically for the control-ointment versus hydromorphone-ointment subjects.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Self-identified as normal, healthy volunteers age 18-65.

Exclusion Criteria:

  • Known bleeding disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00177060


Locations
Layout table for location information
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Hordinsky, Maria K., MD
Investigators
Layout table for investigator information
Principal Investigator: Maria Hordinsky, MD University of Minnesota
Principal Investigator: Robert Hebbel, MD University of Minnesota
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00177060    
Other Study ID Numbers: 0308M50994
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: March 1, 2010
Last Verified: February 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Hydromorphone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents